Biologics for immunosuppression
Biologics should be used after considering other less invasive treatments. Before using biologics to treat psoriasis, easier treatments of moisturizer or light therapy can provide relief. Other drugs which can provide relief include acitretin, cyclosporine, and methotrexate, but since these drugs have their own major side effects, doctors and patients should discuss whether to try one of these or a biologic first.
Other contraindications for biologics include cancer, certain neurologic disorders, being pregnant or breastfeeding, history of heart failure, or history of tuberculosis.
Biologics are the second generation of biopharmaceutical products. The first generation were the biopharmaceutical products which could be extracted from organisms without biotechnology from the Information Age. Those first generation products include blood for transfusion, early insulin extracted from animals, and vaccines from eggs.
Society and cultureEdit
The explanation for this is that while "biologic" or "biopharmaceutical" refers to the chemical composition of medications which might be used to treat a range of medical conditions, when the term "biologic" became popular, many biologic medications available provided immunosuppression.
Another related term, biosimilar, is a term for describing a biopharmaceutical product which seems so close in composition and effect to another that they are functionally identical. In this context, some publications describe "biologics" as "biosimilars".
- "Biologic Medications for Psoriasis". Consumer Reports. August 2014. Retrieved 17 July 2017.
- Singh, JA; Christensen, R; Wells, GA; Suarez-Almazor, ME; Buchbinder, R; Lopez-Olivo, MA; Tanjong Ghogomu, E; Tugwell, P (7 October 2009). "Biologics for rheumatoid arthritis: an overview of Cochrane reviews". The Cochrane Database of Systematic Reviews (4): CD007848. doi:10.1002/14651858.CD007848.pub2. PMID 19821440.
- Singh, JA; Wells, GA; Christensen, R; Tanjong Ghogomu, E; Maxwell, L; Macdonald, JK; Filippini, G; Skoetz, N; Francis, D; Lopes, LC; Guyatt, GH; Schmitt, J; La Mantia, L; Weberschock, T; Roos, JF; Siebert, H; Hershan, S; Lunn, MP; Tugwell, P; Buchbinder, R (16 February 2011). "Adverse effects of biologics: a network meta-analysis and Cochrane overview". The Cochrane Database of Systematic Reviews (2): CD008794. doi:10.1002/14651858.CD008794.pub2. PMID 21328309.
- D'Haens, G. (1 May 2007). "Risks and benefits of biologic therapy for inflammatory bowel diseases". Gut. 56 (5): 725–732. doi:10.1136/gut.2006.103564. PMC 1942157. PMID 17440187.
- Dubey, Ashok K.; Handu, Shailendra S.; Dubey, Suparna; Sharma, Prashant; Sharma, K. K.; Ahmed, Qazi M. (2011). "Belimumab: First targeted biological treatment for systemic lupus erythematosus". Journal of Pharmacology & Pharmacotherapeutics. 2 (4): 317–319. doi:10.4103/0976-500X.85930. ISSN 0976-500X. PMC 3198539. PMID 22025872.
- Zimney, Ed (2 December 2008). "Understanding biologics: How they differ from drugs and why they cost more - Dr. Z's Medical Report". Everyday Health. Retrieved 17 July 2017.
- "What biological therapies are". www.cancerresearchuk.org. Cancer Research UK. 25 Nov 2014.
- Center for Biologics Evaluation and Research (5 August 2015). "What Are "Biologics" Questions and Answers". www.fda.gov. Retrieved 17 July 2017.
- "Biopharmaceutical". ScienceDaily. Retrieved 2018-12-07.
- Food and Drug Administration (27 August 2015). "Information for Consumers (Biosimilars)". www.fda.gov.
- The Changing Drug Landscape - Biologics: the high cost of breakthrough medicine, an 8-minute video by Empire Life about the cost of biologics